The WATCHMAN left atrial appendage closure device for patients with atrial fibrillation: current status and future perspectives.

Abstract

INTRODUCTION:

Atrial fibrillation (AF) is associated with an increased risk of stroke. Stroke prevention with oral anticoagulation (OAC) is recommended in AF patients at increased risk of stroke. The left atrial appendage (LAA) is the main source of thrombus formation in AF patients. The WATCHMAN percutaneous LAA closure (LAAC) device may serve as an alternative to OAC overcoming disadvantages including the risk of (major) bleeding.

AREAS COVERED:

This review will focus on LAAC with the Watchman device for stroke prevention in AF patients. Current status, available literature, clinical safety and efficacy will be summarized. Furthermore, the future perspectives of Watchman will be discussed.

EXPERT OPINION:

LAAC with Watchman appears a promising, safe, and effective alternative to OAC. Ongoing and future studies to consolidate the position of Watchman should focus on comparative safety and efficacy of different LAAC devices, patient selection, various post-procedural antithrombotic regimens, head-to-head comparisons with NOAC, better understanding of device-related thrombus, and the role of the LAA in the propagation of non-valvular AF. This research may attribute to a paradigm shift in which LAAC no longer serves as a 'last resort' treatment for AF patients ineligible for OAC but may serve as a second-line or even first-line treatment option for AF patients.

• Authors: Lisette I S Wintgens, Moniek Maarse, Martin J Swaans, Benno J W M Rensing, Vincent F Van Dijk, Lucas V A Boersma
• Journal: Expert review of medical devices (Expert Rev Med Devices) Vol. 17 Issue 7 Pg. 615-626 (Jul 2020) ISSN: 1745-2422 [Electronic] England
• PMID: 32543911 (Publication Type: Journal Article, Review)

Chemical References

• Anticoagulants

Topics

• Anticoagulants (adverse effects)
• Atrial Appendage (pathology)
• Atrial Fibrillation (complications, therapy)
• Cost-Benefit Analysis
• Equipment and Supplies (adverse effects, economics)
• Humans
• Treatment Outcome